
Long-held fears about testosterone therapy are giving way to evidence. In this Urology Times webinar, moderator Amy M. Pearlman, MD, is joined by Abraham Morgentaler, MD, FACS; Mohit Khera, MD, MBA, MPH; and Helen L. Bernie, DO, MPH, members of the December 2025 FDA expert panel on testosterone therapy for men. They review the FDA’s label revisions, challenge the belief that testosterone fuels prostate cancer, weigh Schedule III status, and answer audience questions on treatment targets, fertility, and formulations.



















